Innovation Drives the Future——Though the Journey is Long, Perseverance Leads to Success Recently, Shanghai Lishan Biotech Co., Ltd. has received exciting news—it has officially been recognized as a National High-Tech Enterprise and has been awarded the "High-Tech Enterprise Certificate" jointly issued by the Shanghai Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Municipal Office of the State Administration of Taxation. This recognition marks that Lishan Biotech has met the national standards for high-tech enterprises in areas such as innovative drug development, technological innovation, and achievement commercialization, serving as a strong endorsement of the company's sustained innovation capabilities and scientific research strength.   AI-Empowered: The Innovation Engine f...

At the beginning of the Year of the Horse, on the afternoon of February 26th, the "New Overseas Chinese Innovation and Entrepreneurship in Shanghai" activity, organized by the Shanghai Federation of Returned Overseas Chinese to visit overseas Chinese enterprises and facilitate practical work, entered Zhangjiang Pharma Valley and held a thematic seminar at Lishan Biotech. A delegation comprising Qi Quansheng, Party Secretary and Chairman of the Shanghai Federation of Returned Overseas Chinese; Guo Qing, Vice Chairman of the Municipal Federation and concurrently Party Secretary and Chairman of the Pudong New Area Federation; and Cheng Dong, Chairman of the Zhangjiang Science City Federation, among others, visited the company. Li Zhi, Deputy Director of Corporate Communications at Junshi Biosciences, and Shang Jing, Executive D...

BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results   Rehovot, Israel and Shanghai, China – February 4, 2026 – Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biotech Co., Ltd. ("Lishan Biotech"), a China-based clinical-stage biotechnology company focused on innovative therapies in the fields of immunity and inflammation, today announced that Biomica Ltd. ("Biomica"), Evogene’s subsidiary and Lishan Biotech entered into an exclusive worldwide licensing agreement for BMC128 (designated as LS-LBP-002 by Lishan Biotech), a first-in-class microbiom...

In order to highlight the innovation and vitality of Zhangjiang's life science industry, the WeChat official account of "Zhangjiang Pharmaceutical Valley" launched the column of "New Talents of Pharmaceutical Valley", and invited new enterprises of Zhangjiang Pharmaceutical Valley to have in-depth dialogue and decode innovation. In this issue, we will have a conversation with Dr. William Chen, Chairman of Shanghai Lishan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Lishan Biotech"), to learn how the company has embarked on a path of cross-border integration and innovation. William Chen, Chairman of Lishan Biotechnology   At the National Finals of the 3rd National Postdoctoral Innovation and Entrepreneurship Competition, which concluded in October 2025, Dr.William Chen, Chairman of Lishan Biotech, led the "Inte...